MedPath

A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients

Not Applicable
Completed
Conditions
HIV Infections
Registration Number
NCT00002207
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

The purpose of this study is to compare the effectiveness of taking didanosine (ddI) once a day plus stavudine (d4T) twice a day with taking ddI twice a day plus d4T twice a day. This study also examines the safety of giving ddI with d4T in the short-term.

Detailed Description

Patients are randomized to receive ddI given either qd or bid in combination with d4T given bid (no doses specified).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (13)

ID Care Inc

🇺🇸

Somerville, New Jersey, United States

Fanno Creek Clinic

🇺🇸

Portland, Oregon, United States

Dr Iraj Mirshahi

🇺🇸

Richmond, Virginia, United States

Clinsites / Sorra Research Ctr

🇺🇸

Birmingham, Alabama, United States

Indiana Univ School of Medicine / Dept of Infect Dis

🇺🇸

Indianapolis, Indiana, United States

New Jersey Community Research Initiative

🇺🇸

Newark, New Jersey, United States

Anderson Clinical Research

🇺🇸

Pittsburgh, Pennsylvania, United States

Univ of Texas Southwestern Med Ctr of Dallas

🇺🇸

Dallas, Texas, United States

Univ of Texas Med Branch

🇺🇸

Galveston, Texas, United States

Houston Clinical Research Network

🇺🇸

Houston, Texas, United States

Shared Med Research Foundation

🇺🇸

Tarzana, California, United States

Hampton Roads Med Specialists

🇺🇸

Hampton, Virginia, United States

Medicine Faculty Associates

🇺🇸

Ypsilanti, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath